tbuckley/cabot-search huggingface dataset:
Abstract 881: Polymorphisms of <i>PUMA,</i> a BH3-only pro-apoptotic gene, modify risk of squamous cell carcinoma of head and neck associated with HPV16 infection
Authors: ZiYuan Zhou, Guojun Li, Zhensheng Liu, Li-E Wang, Erich M. Sturgis, Qingyi Wei
Journal: Cancer Research (2011)

Abstract PUMA (p53 upregulated modulator of apoptosis) and Noxa (Latin for damage), as well as their common target MCL-1 (myeloid cell leukemia 1), respond to human papillomavirus 16 (HPV16) oncoprotein E6-mediated p53 degradation or E7-mediated pRb inactivation, and therefore may alter cancer susceptibility through the PUMA (Noxa)-MCL1-apoptosis mechanism. In this case-control study of 380 cases and 335 cancer-free matched controls, we evaluated HPV16 seropositivity and two single nucleotide polymorphisms (SNPs) in the promoter region for each gene (rs3810294 and rs2032809 for PUMA, rs4558496 and rs9957673 for Noxa, rs9803935 and rs3738485 for MCL1) to examine their possible associations with risk of squamous cell carcinoma of head and neck (SCCHN). Of the 6 SNPs, both two SNPs of PUMA were significantly associated with 1.5-fold increased SCCHN risk in a dominant model. When we include the HPV16 seropositivity in the model, the risk of SCCHN was significantly increased in an allele-dose effect manner (Ptrend&amp;lt; 0.0001 for each SNP, respectively). Notably, in the site-stratified analysis, oropharyngeal cancer risk was dramatically increased, particularly among minor alleles carriers having the HPV16 L1 seropositivity with OR (95%CI) of 13.8 (5.4-35.5) for rs3810294 and 8.1 (4.3-15.0) for rs2032809 (both Ptrend &amp;lt; 0.0001). These data suggest some synergistic effects between PUMA variants and HPV16 seropositivity on susceptibility to SCCHN, especially in those cases with HPV-related oropharyngeal cancer. Additionally, the modifying effect of PUMA variants on oropharyngeal cancer associated with the HPV16 L1 seropositivity was more predominant in never-smokers, never-drinkers and young subjects. Our results suggest that PUMA promoter polymorphisms, synergistically interacting with HPV16 L1 seropositivity, modify risk of HPV-related oropharyngeal cancer. Further molecular and epidemiologic studies with larger samples are needed to validate our findings. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 881. doi:10.1158/1538-7445.AM2011-881
Abstract 5125: Functional genomic strategies to identify oncogenes in breast cancer
Authors: Stephen Guest, Ramsi Haddad, Joe Gray, Stephen Ethier
Journal: Cancer Research (2012)

Abstract During the process of tumorigenesis and tumor progression cancer cells acquire an array of genetic alterations. The theory of oncogene addiction proposes that a small portion of these alterations generate driver oncogenes that are critical for maintaining the transformed phenotype. Strong support for this theory comes from the identification and subsequent therapeutic targeting of individual driver oncogenes that has resulted in significant clinical responses. However, in solid tumors that contain multiple driver oncogenes, these responses are not durable and it is therefore likely that multiple oncogenes will need to be identified and targeted in these tumors in order to reverse the transformed phenotype and effect durable clinical responses. Identifying multiple driver oncogenes among the large number of mutated/amplified genes that are present in most solid tumors is a nontrivial task that will require novel approaches. In this study, we have developed an approach that combines exome sequencing, array comparative genomic hybridization, expression analysis and genome-wide, RNAi-based functional screening to identify driver oncogenes that are functioning in individual cell lines derived from human tumors. In a pilot study using this approach we have shown that of the 583 amplified genes in the SUM225 breast cancer cell line only 45 are hits in the RNAi-based functional screen. Similarly, of the 806 genes that are mutated in this cell line only 26 are hits in the RNAi-based functional screen. Interestingly, the SMPD3 gene that was both amplified and a hit in the functional screen also contained a point mutation and this point mutation was present in another HER2 positive breast cancer cell line, SUM190. The identification of SMPD3 as a likely driver oncogene in the SUM225 and SUM190 cell lines highlights the power of an approach that combines sequence and copy number data with functional screening to identify driver oncogenes. Future analysis will incorporate expression data to further refine this approach. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5125. doi:1538-7445.AM2012-5125
Complication of endoscopic papillary large-balloon dilation using double-balloon endoscopy for biliary stones in a postoperative patient
Authors: Masaaki Shimatani, Makoto Takaoka, Toshiyuki Mitsuyama, Hideaki Miyoshi, Tsukasa Ikeura, Kazuichi Okazaki
Journal: Endoscopy (2014)

Recently, extraction of stones by endoscopic papillary large-balloon dilation (EPLBD) using CRE balloons (Boston Scientific Japan, Tokyo, Japan; 5.5 cm long, 10 – 12, 12 – 15, and 15 – 18 mm in diameter) has been shown to be an effective modality, which is being widely used in difficult situations for patients with normal anatomy [1] [2]; however, few papers have reported on the use of EPLBD in patients with altered gastrointestinal anatomy [3] [4] [5], and fewer still on its complications.
Abstract LB-110: CDK4 activation is a key step in ELF alteration and haploinsufficeny of <i>cdk4</i> prevents HCC formation in <i>elf+/−</i> mice
Authors: Hye Jung Baek, Michael J. Pishvaian, Kwan Ho Cho, Bibhuti Mishra, E. Premkumar Reddy, Lopa Mishra, Sang Soo Kim
Journal: Cancer Research (2010)

Abstract Transforming growth factor (TGF-) is an important regulator of cell growth and the loss of TGF- signaling occurs early in carcinogenesis. Embryonic liver fodrin (ELF), an interaction protein of Smads, is involved in TGF- signaling. Significantly, elf+/− mice spontaneously developed the hepatocellular cancer (HCC) and lots of human HCC exhibited decreased or absent ELF expression. Here, we investigated how alteration of ELF led the deregulation of cell cycle progression and eventually formed the HCC. Up regulation of ELF expression led the decreased phosphorylation of Rb protein with the remarkable reduction of CDK4 than other CDKs and cyclins. Then, inhibition and downregulation of CDK4 by inhibitor and siRNA rescued the abnormality of G1/S transition and over-activation of Rb phosphorylation caused by infection of ELF shRNA in SNU475 HCC cell line. We further demonstrated the biochemical communications using immunoprecipitation that ELF interacted CDK4, and Smad3 in competitive way and TGF-ß-dependent manner. In addition, haploinsufficieny of cdk4 in elf+/− mice displayed the dramatic decrement of HCC formation than elf+/− mice with decreased Ki-67 and c-myc expressed hepatocyte in liver tissue. Thus, in response to ELF deficiency, the activation of CDK4 contributes to the phosphorylation of Rb protein, which leading to facilitated G1/S transition. Our data highlight CDK4 as an attractive target for pharmacologic inhibition and importance of elf+/− model to demonstrate pre-clinical efficacy in the treatment of HCC with ELF alteration. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-110.
AB0641 High Frequency Ultrasound of Skin Involvement in Systemic Sclerosis – A Follow-Up Study
Authors: R. Hesselstrand, J. Carlestam, K. Andréasson, M. Wildt, G. Sandqvist
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Skin thickness in systemic sclerosis (SSc) may be measured by high frequency ultrasound. Most studies have a cross sectional design. <h3>Objectives</h3> The aim of the study was to study the changes in high frequency ultrasound of the skin during one year of follow-up in SSc. <h3>Methods</h3> In this retrospective study we identified 113 patients in whom ultrasound examination was performed at baseline and at the one year follow-up at 5 predefined sites. 37 were classified as diffuse cutaneous SSc (dcSSc) and 76 as limited cutaneous SSc (lcSSc). <h3>Results</h3> There were significant changes in skin thickness of the chest (p=0.002) and in the total sum of skin thickness (p=0.008) during the observation time. The changes of skin thickness of the phalanx, back of hand, forearm and lower leg were however not significant. There was an inverse correlation between total skin thickness and disease duration (r<sub>S</sub>: -0.26; p=0.005). Anti RNA polymerase III (ARA) positive patients displayed significantly larger variance in change of total skin thickness than patients with centromeric antibodies (ACA) (p=0.003), anti topoisomerase I antibodies (ATA) (p=0.017), and ANA without ACA, ATA or ARA (p=0.045). Paired T-test showed that total skin thickness was reduced in the 18 patients treated by Cyclophosphamide (p=0.015) whereas no reduction of total skin thickness was seen after treatment with Azathioprine, Methotrexate or Mycophenylatemofetil. 45 patients treated with Prednisolone showed a reduced total skin thickness (p=0.015) whereas there was no difference in patients not treated with Prednisolone. The ultrasound measurements of skin thickness correlated to serum-cartilage oligomeric matrix protein (serum-COMP) (r<sub>S</sub>: 0.38; p=0.001) and the modified Rodnan skin score (mRSS) (r<sub>S</sub>: 0.51; p=0.001) at baseline and the 1-year follow-up (r<sub>S</sub>: 0.47; p&lt;0.001 and r<sub>S</sub>: 0.51; p&lt;0.001 respectively). At 1-year follow-up total skin thickness also correlated to hand mobility in scleroderma (HAMIS) values (r<sub>S</sub>: 0.47; p&lt;0.001). Changes in total skin thickness correlated with changes in mRSS (r<sub>S</sub>: 0.32; p=0.001) and HAMIS (r<sub>S</sub>: 0.36; p=0.004) during the same time period. <h3>Conclusions</h3> In SSc, measurement of skin thickness by high frequency ultrasound, enables us to better understand the complex process of skin fibrosis in regard to the evolvement of oedema and skin contractions and the diversity between phenotypes and effects of therapies. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4209
AB1070 Adverse events with short vs long-term pegloticase therapy in trials of refractory chronic gout:
Authors: M. Wolfson, C. Rehrig, K. Bahrt
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Pegloticase was approved for the treatment of refractory chronic gout in the U.S. in 2010. The pegloticase registration program comprised 2, 6-month placebo-controlled Phase 3 trials (RCTs) followed by an open-label (OL) safety study for a total treatment duration of up to 3 yrs. Pegloticase was tested at two dosing regimens; 8 mg q2weeks (approved) and 8 mg q4weeks and patients had the option of changing regimens during the OL extension study. <h3>Objectives</h3> To evaluate short and long-term safety with the approved biweekly dose of pegloticase in patients who received this regimen for the full RCT and extension study period. <h3>Methods</h3> A subgroup of patients was identified from the pegloticase Phase 3 clinical trials who did not switch pegloticase dosing regimen (n=143) for the full duration of their exposure. The pattern and timing of all treatment emergent adverse events was evaluated for these patients during the 2.5 yrs of treatment (long term treatment) and compared with the AE profile in the pooled RCTs (short-term treatment). Adverse events were analyzed descriptively (total number per patient per year), and by type, for these patients receiving pegloticase q2weeks and q4weeks. <h3>Results</h3> The Table shows the number, total exposure and rates of all adverse events, along with clinically relevant classes of AEs, for patients receiving a consistent dosing regimen of biweekly or monthly pegloticase. Rates of AEs were not increased with long term vs. short term pegloticase exposure. As may have been expected, gout flares were less common with long term pegloticase use. <h3>Conclusions</h3> This analysis of adverse events in patients receiving a consistent regimen of pegloticase shows that the rate of all adverse events was not increased with long term vs. short term therapy. Gout flares and infusion-related reactions were less common with the approved q2week dose vs. the q4week dose for both short-term and long-term treatment. No evidence of new safety concerns or increased adverse events was revealed in this analysis of long-term (up to 3 yrs) pegloticase use. <h3>Disclosure of Interest</h3> M. Wolfson Shareholder of: Savient, Employee of: Savient, C. Rehrig Shareholder of: Savient, Employee of: Savient, K. Bahrt Shareholder of: Savient, Employee of: Savient
SP0148 The Network of Parents with Children Who Have Arthritis in Germany
Authors: B. Markus
Journal: Annals of the Rheumatic Diseases (2014)

<h3></h3> The German League against arthritis contents of 16 regional associations (one for each region in Germany) and 3 membership associations (Bekhterev9s disease, Scleroderma, Lupus erythematosus). There are parent groups in all of the regional associations. They meet to get and give information, discuss problems, give personal advice, change phone numbers/addresses and emails and meet for weekend-activities with their families. Some parents voluntarily support the associations. The parents elect a parent representative for their association. The elected parent representatives meet once a year at a workshop or alternately at the BUKO (the German conference of parents and young rheumatics). At the BUKO they work out political demands related to rheumatism. And they elect a Committee and one nationwide parent representative. There a few parents, who voluntarily work a telephone-hotline especially for parents to give information and support. Other parents answer questions in the forum of the homepage of the German League against Rheumatism. The committee contents of 5 parents who support the German League against Rheumatism with writing reports for the magazine "mobile", give statements on political issues related to rheumatism, organize the national meetings (workshop or BUKO),the design of the homepage and create the newsletter, which is sent to all registered parents in Germany. The nationwide parent representative represents all German parents with children who have arthritis in national or international meetings, congresses, social organizations and of course maintains contacts to all other parents via email or phone. This way a secured connection between and to all parents in Germany who have children with arthritis is guaranteed. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.6111
AB1017 Iliac wing fracture: An unusual osteoporotic fracture
Authors: E. Casado, I. Vázquez, M. Larrosa, C. Galisteo, P. Torner, J. Gratacόs
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Pubic rami or sacral fractures are insufficiency fractures relatively frequent among patients with osteoporosis. However iliac wing fractures are rare, and most cases reported in the literature correspond to previously treated patients with osteoporosis and previous fractures in other sites<sup>1</sup>. <h3>Objectives</h3> To describe the clinical and radiological features of patients with iliac wing fractures diagnosed at the University Hospital of Sabadell in the last 20 years. <h3>Methods</h3> Descriptive study. A review of medical records of all out-patients with pelvic fractures referred for diagnosis and treatment of osteoporosis to the Rheumatology department, University Hospital of Sabadell (reference population 400,000) since 1990. We selected those with the diagnosis of insufficiency fracture of the iliac wing (without trauma or falling from one's own height). After confirming the presence of the iliac wing fracture we proceeded to review the patient's medical history to record clinical and demographic data. Phospho-calcium metabolism parameters and thoracic and lumbar X-ray were also reviewed in all the patients at the time of the fracture. <h3>Results</h3> We found 5 iliac wing fractures in 4 patients (3 women). Mean age 58.8±2.8 years (range 43-73). One patient had a simultaneous bilateral fracture. In three cases there were pelvic ring concomitant fractures (pubic rami and/or sacrum). No patient had been previously diagnosed with osteoporosis or fractures. All patients had mechanical pain in their buttock or groin. Risk factors for fractures, other than age, were found in three patients: hyperthyroidism in one case, HIV infection and antiretroviral therapy in the second case, and rheumatoid arthritis under chronic glucocorticoids in the third case. Three of the four patients had hypovitaminosis D (25(OH)D &lt;25 ng/ml), whereas PTH was normal in all cases. No patient had morphometric vertebral fractures. <h3>Conclusions</h3> The iliac wing fractures in our series are mostly in postmenopausal women previously undiagnosed and untreated for osteoporosis, with concomitant pelvic ring fractures. Most cases occur in patients with risk factors for fracture and concomitant hypovitaminosis D. <h3>References</h3> Chary-Valckenaere I, Blum A, Péré P, GRAUBUENDEN B, Pourel J, Gaucher A. Insufficiency fractures of the ilium. Rev. Rhum. (Engl. Ed) 1997; 64 (10): 542-8. <h3>Disclosure of Interest</h3> None Declared
PERFORMANCES OF ELASTO-FIBROTEST®, A COMBINATION BETWEEN FIBROTEST AND LIVER STIFFNESS MEASUREMENTS FOR ASSESSING THE STAGE OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C
Authors: T. Poynard, V. de Ledinghen, J.P. Zarski, C. Stanciu, M. Munteanu, J. Vergniol, J. France, A. Trifan, G. Lenaour, J.C. Vaillant, V. Ratziu, F. Charlotte
Journal: Journal of Hepatology (2012)
EARLY MEASUREMENT OF LEFT VENTRICULAR EJECTION FRACTION BY CARDIAC MAGNETIC RESONANCE AFTER MYOCARDIAL INFARCTION IS SUPERIOR TO GADOLINIUM DELAYED-ENHANCEMENT IN PREDICTING LATE REMODELING
Authors: Anthony A. Holmes, Jorge Romero, Nidhish Tiwari, Newton Phuong, David Goodman-Meza, Stuart Cohen, Leila R. Gharai, Cynthia Taub, Jeffrey Levsky, Linda Haramati, John Fisher, Mario Garcia
Journal: Journal of the American College of Cardiology (2015)
EFFECT OF RENAL SYMPATHETIC DENERVATION ON CARDIAC SYMPATHETIC NERVE ACTIVITY ASSESSED WITH IODINE 123 METAIODOBENZYLGUANIDINE SCINTIGRAPHY
Authors: Andrius Berukstis, Donatas Vajauskas, Urte Gargalskaite, Nerijus Misonis, Marius Miglinas, Birute Petrauskiene, Greta Burneikaite, Justinas Ivaska, Aleksandras Laucevicius
Journal: Journal of the American College of Cardiology (2015)
ABMT Trials Evaluate Quality of Life
Authors: L. Schwab
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article ABMT Trials Evaluate Quality of Life Get access Linda Schwab Linda Schwab Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 16, 21 August 1991, Page 1137, https://doi.org/10.1093/jnci/83.16.1137 Published: 21 August 1991
P5-13-06: Lipidomic Profile Predicts Pathologic Complete Response to Neoadjuvant Weekly Paclitaxel Treatment.
Authors: G Facina, NMCT Calux, MFR Silva, TCS Bonetti, ACP Nazario, IDCG Silva
Journal: Cancer Research (2011)

Abstract BACKGROUND: Neoadjuvant chemotherapy is one of the main strategies for patients with advanced breast cancer. The taxane paclitaxel have an important role in inhibiting microtubule polymerization and this mechanism prevents cells from entering into the mitotic phase. The therapeutic efficacy and toxicity profile of weekly paclitaxel administration have been showed since 90s. Lipidomics may be defined as the large-scale study of pathways and networks of cellular lipids that is involved in biological systems. In the present study our aim was to evaluate the possibility to identify a lipidomic signature of good and bad responsers to neoadjuvant chemotherapy. PURPOSE: To analyze and identify the lipid fingerprint in tumor biopsy of advanced breast cancer patients who get a complete pathologic response (CPR) with weekly paclitaxel treatment and compare this with the group who get no response. MATERIALAND METHODS: Seventy eight patients with clinical stage IIIA breast cancer were selected to receive the neoadjuvant treatment with weekly paclitaxel (for a total of 12 doses — 80mg/m2). Fifty eight patients completed the treatment purpose. Seven presented CPR (Group A) and 5 showed progressions (Group B). The lipids were extracted from biopsies and submitted to matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS). MALDI-MS spectra were acquired in the positive ion and reflectron modes using Synapt Q-ToF mass spectrometers (Waters, Manchester, UK). The spectra were acquired in the m/z 700–1200 range. From each spectrum the most intense ions were considered as the starting point of searching m/z values which were clearly distinct from noise level in the spectra were included in the principal component analysis (PCA). RESULTS: The PCA analysis of the mass spectra shows that groups can be resolved via their MALDI-MS lipid profiles, which suggest the patients who presented CPR can present distinct lipid fingerprint in the tumor biopsy compared to patients who showed progressions. CONCLUSION: After genomic and proteomic innovations, it turns necessary to explore metabolic processes at the system level. Lipidomics is a developing strategy for functional genomics, since there is growing evidence that lipids are structural biomolecules, which have important function as signal transduction processes, second messenger molecules or their precursors. Is possible that lipidomic profile of tumor specimen could help us to select the patients with advanced breast cancer that might present complete pathologic response by weekly paclitaxel treatment. This study will be continued to confirm this results and carried the identification of the lipids based on earlier studies and MS/MS data using lipidmaps and chemspider databases. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-13-06.